Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0M | $23.6M | $25.6M | $30.3M | $93.5M | $242M | $442M | $605M |
| Revenue growth | — | 81.3% | 8.6% | 18.0% | 208.8% | 158.5% | 82.7% | 37.1% |
| Gross profit | $5.73M | $13.9M | $16.6M | $21.2M | $65.3M | $154M | $262M | $363M |
| Gross margin | 44.1% | 58.7% | 64.9% | 69.9% | 69.8% | 63.8% | 59.4% | 59.9% |
| Operating income | -$20.2M | -$29.6M | -$26.4M | -$39.4M | -$31.4M | -$28.7M | $37.5M | $109M |
| Operating margin | -155.5% | -125.4% | -102.9% | -130.3% | -33.6% | -11.9% | 8.5% | 17.9% |
| Net income | -$23.8M | -$33.5M | -$28.7M | -$44.2M | -$36.2M | -$25.0M | $35.5M | $190M |
| Net margin | -182.5% | -142.1% | -112.1% | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% |
| EPS (diluted) | -$17.48 | -$2.36 | -$1.16 | -$1.60 | -$1.23 | -$0.77 | $1.01 | $4.87 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.0M | -$32.3M | -$30.3M | -$28.9M | -$45.8M | -$13.0M | $48.8M | $193M |
| Capital expenditures | $418K | $165K | $455K | $3.52M | $11.9M | $152M | $130M | $59.3M |
| Free cash flow | -$26.4M | -$32.5M | -$30.7M | -$32.4M | -$57.7M | -$165M | -$80.9M | $134M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.7M | $20.6M | $25.1M | $26.1M | $202M | $395M | $337M | $489M |
| Total assets | $42.2M | $105M | $152M | $135M | $277M | $706M | $804M | $1.07B |
| Total liabilities | $47.9M | $50.6M | $48.1M | $67.0M | $89.8M | $569M | $575M | $595M |
| Long-term debt | $33.7M | $34.1M | $34.7M | $35.2M | $58.7M | — | — | — |
| Shareholders' equity | -$192M | $54.6M | $104M | $67.9M | $187M | $137M | $229M | $473M |
| Retained earnings | -$336M | -$369M | -$398M | -$442M | -$479M | -$504M | -$468M | -$278M |
| Shares (wtd avg diluted) | — | — | 24.7M | 27.6M | 29.6M | 32.5M | 35.2M | 40.5M |
Every figure is extracted from TransMedics Group, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.